{
  "abstract": "Background: Pancreatic cancer remains one of the most aggressive solid malignancies. The majority of patients present with locally advanced or metastatic disease, limiting treatment options to systemic chemotherapy. Conventional chemotherapy forms the backbone of the standard-of-care regimen and offers modest but significant survival benefits.\n\nMain body: This review discusses currently established standard-of-care regimens and cutting edge clinical trials which aim to enhance chemotherapy efficacy in pancreatic cancer. Pancreatic cancer’s distinct pathological features—including its high metastatic potential, inherent chemoresistance, dense desmoplastic stroma, and profoundly immunosuppressive tumour microenvironment—underscore the rationale for the clinical development of chemosensitizing agents. As mechanisms of chemoresistance continue to be uncovered, new therapeutic avenues are emerging that aim to enhance the efficacy of chemotherapy. Emerging targets including KRAS, MTAP, EGFR, Claudin 18.2, and WEE1, which present unique vulnerabilities for rational combination therapies, are discussed.\n\nConclusion: Given the central role of chemotherapy in pancreatic cancer treatment, ongoing clinical strategies that improve its efficacy are essential to achieving better outcomes for patients.",
  "abstract_shown": true,
  "affiliations": [
    "Discipline of Surgery, School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland",
    "Trinity St. James’s Cancer Institute, Trinity College Dublin, Dublin, Ireland",
    "Nanomedicine Group and Laboratory for Biological Characterisation of Advanced Materials (LBCAM), Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "David Hackett"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Laura E. Kane"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Adriele Prina-Mello"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Stephen G. Maher"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3pqa22fvymm4f.bib",
  "cited_by": 0,
  "doi": "10.1186/s12916-026-05134-x",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13746621/",
  "id": "3pqa22fvymm4f",
  "issns": [
    "1741-7015"
  ],
  "landing_url": "https://doi.org/10.1186/s12916-026-05134-x",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Review"
    ],
    [
      "openalex",
      "2730|Pancreatic and Hepatic Oncology Research"
    ]
  ],
  "openalex": "W7202214691",
  "pdf_url": null,
  "pmcid": "PMC13746621",
  "pmid": "43004418",
  "published": "2026-08-11",
  "publisher": "BMC",
  "ris": "https://research.draconitic.com/paper/3pqa22fvymm4f.ris",
  "sources": [
    {
      "first_seen": "2026-11-11T12:23:58Z",
      "native_id": "PMC13746621",
      "source": "pmc",
      "url": "https://doi.org/10.1186/s12916-026-05134-x"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Pancreatic and Hepatic Oncology Research",
      "subfield": "oncology"
    }
  ],
  "title": "Current and emerging strategies to enhance chemotherapeutic efficacy in pancreatic ductal adenocarcinoma",
  "title_text": "Current and emerging strategies to enhance chemotherapeutic efficacy in pancreatic ductal adenocarcinoma",
  "type": "peer-reviewed",
  "updated_at": "2026-11-13T12:23:10Z",
  "url": "https://research.draconitic.com/paper/3pqa22fvymm4f",
  "venue": "BMC Medicine",
  "versions": []
}